Key result
Finerenone linked to ~56% lower UACR in nondiabetic CKD.
Why the study?
Data on the efficacy and adverse effects of finerenone in nondiabetic chronic kidney disease are limited, particularly regarding ethnic diversity.
Does finerenone reduce albuminuria and blood pressure in patients with nondiabetic chronic kidney disease?
Population
16 patients with nondiabetic CKD in Riyadh, Saudi Arabia
Comparison
Finerenone treatment before vs after therapy initiation
Design
Single-center retrospective exploratory study
Authors
Loading...
Finerenone was associated with reduced albuminuria in nondiabetic CKD; hypothesis-generating and requires randomized confirmation before practice change.
Observational (n=16)
No
Does finerenone reduce albuminuria and blood pressure in patients with nondiabetic chronic kidney disease?
Absolute Event Rate: 39.3% vs 90%
p-value: p=0.04
Finerenone significantly reduced albuminuria and blood pressure in a small cohort of patients with nondiabetic CKD without causing hyperkalemia or hypotension.
Albakr et al. (2025) conducted an observational in Nondiabetic chronic kidney disease (n=16). Finerenone vs. Baseline was evaluated on Urine albumin-to-creatinine ratio (UACR) (p=0.04). Finerenone treatment significantly reduced the urine albumin-to-creatinine ratio from 90.0 to 39.3 mg/g (p=0.04) in patients with nondiabetic chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: